In a transgenic rat-neu (FVBN202) model of early-stage breast cancer and in pilot human specimens, Aqbi and colleagues (Breast Cancer Research, 2020) showed that dormant tumor cells appear at the primary site and in lungs and liver long before any visible metastasis, and that retention of dormancy is associated with a predominance of infiltrating CD4+ and CD8+ T effector (Te) and T effector-memory (Tem) cells; tumor-sensitized T cells also inhibited regrowth of dormant cells ex vivo. The authors explicitly left open whether Te/Tem cells causally maintain dormancy or merely accompany it, whether dormant populations enriched for slow-cycling Ki67-low indolent cells relapse faster than quiescent Ki67-negative-predominant populations after tumor excision, what explains organ-dependent (lung versus liver) differences in dormancy composition and therapy-associated PD-L1/PD-1 immunoediting, and whether immunotherapy administered during the clinical dormancy window can safely prevent distant recurrence. Adjacent models have since provided interventional evidence that specific T-cell subsets can maintain breast cancer metastatic dormancy (CD39+PD-1+CD8+ cells acting through TNF-alpha and IFN-gamma, 2021) and that T-cell immunotherapies can eliminate dormant disseminated tumor cells preclinically (2024), but the source's cause-effect question for Te/Tem in early breast cancer, the composition-dependent relapse kinetics, the organ-specific immunoediting mechanism, and clinical translation all remain unresolved.

Background

Tumor dormancy is the state in which disseminated tumor cells (DTCs) persist in distant organs for months to years without forming measurable outgrowths, before reactivating to seed overt metastases; in breast cancer, these late relapses, not the primary tumor, are the main cause of mortality. Two cellular dormancy states are distinguished by the proliferation marker Ki67, a nuclear antigen expressed in cycling cells: quiescent dormancy (Ki67-negative, G0-arrested cells that do not divide) and indolent dormancy (Ki67-low, slow-cycling cells whose sluggish proliferation is counterbalanced by cell death). Because dormant cells are not dividing, they resist chemotherapy and radiation, and there is no palpable lesion to remove, which is why immune-based approaches are considered the only promising modality against them.

The immune system's relationship to dormancy is old but unsettled. The concept of immune equilibrium - adaptive immunity holding occult tumor cells in check without eliminating them - was established in chemically induced and transplanted-tumor models, and tissue-resident memory CD8+ T cells were later shown to keep melanoma cells confined in skin (Park et al., Nature 565:366-371, 2019). What has been missing for breast cancer is equally direct, interventional evidence tied to the earliest phase of dissemination.

The source study (Aqbi et al., Breast Cancer Research 22:116, 2020) used FVBN202 transgenic mice, which express the rat neu oncogene (an ortholog of the human HER2 breast cancer oncogene) in the mammary gland under the mouse mammary tumor virus (MMTV) promoter, and their parental FVB strain, which lacks neu and therefore mounts an alloreactive (anti-rat-neu) immune response. Mouse mammary carcinoma (MMC) cells challenged into the mammary gland spread as neu-positive dormant cells to lungs and liver very early, before any distant metastasis was evident. Dormant cells were quantified by multicolor flow cytometry as viable neu-positive cells that are Ki67-negative (quiescent) or Ki67-low (indolent), together with staining of infiltrating T-cell subsets defined by the adhesion/homing markers CD44 and CD62L: Te effector cells (CD44+CD62L-negative), Tem effector-memory cells (CD44+CD62L-low), Tcm central-memory cells (CD44+CD62L-high), and Tn naive cells (CD44-negative). Dormancy was analyzed under three conditions: no treatment, FAC chemotherapy (5-fluorouracil, Adriamycin/doxorubicin, cyclophosphamide), or FAC followed by adoptive immunotherapy (AIT, transfer of tumor-sensitized immune cells) plus anti-PD-1 antibody, where PD-1 is the T-cell exhaustion marker receptor programmed cell death 1 and PD-L1 its ligand.

Four findings anchor the open question. First, local and distant tumor dormancy in FVBN202 mice was consistently associated with predominance of infiltrating Te and Tem cells. Second, T cells mattered functionally but only partially: ex vivo, tumor-sensitized autologous T cells inhibited regrowth of freshly isolated dormant lung cells without increasing their apoptosis; in vivo, neu-autoreactive T cells from FVBN202 mice prevented regrowth of dormant cells, whereas pre-existing neu-alloreactive T cells in FVB mice prevented dissemination to distant organs altogether. Third, only in the lungs of the FAC/AIT group did dormant cells shift to equal proportions of quiescent and indolent cells, and this shift coincided with increased PD-L1 expression on dormant cells and reduced PD-1 expression on infiltrating T cells - interpreted as therapy-associated tumor immunoediting (immune-driven selection of less-recognizable tumor variants) - while the liver showed no such changes and yielded recoverable dormant cells in culture far later and only in the FAC/AIT group. Fourth, dormant cells that did regrow established new dormancy on re-challenge, with a composition the authors attributed to tumor-intrinsic factors, not yet to defined microenvironmental ones. These are associative observations; the causality, kinetics, organ-logic, and therapeutic exploitation all remained open.

Adjacent literature since has narrowed parts of this agenda without closing it. In a mouse model of breast cancer metastatic dormancy, a CD39+PD-1+CD8+ T-cell population was shown to mediate dormancy interventively: blocking its effector cytokines TNF-alpha and IFN-gamma broke dormancy, and adoptive transfer of the purified subset prevented metastatic outgrowth, with the subset's human frequency correlating with delayed relapse (Tallon de Lara et al., Nature Communications 12:769, 2021). In the liver, hepatic stellate cells were shown to suppress NK-cell-sustained breast cancer dormancy, an organ-specific escape mechanism (Correia et al., Nature 594:566-571, 2021). Conversely, quiescent cancer cells were shown to actively resist T-cell attack by building an immunosuppressive niche (Baldominos et al., Cell 185:1694-1708, 2022). Preclinically, breast DTCs were shown to evade endogenous immunity simply because rare antigen-specific T cells rarely encounter scarce DTCs, and T-cell vaccination, TCR-engineered T cells, or CAR T cells (T cells engineered with a chimeric antigen receptor) each achieved robust DTC elimination (Goddard et al., Cancer Cell 42:119-134, 2024). Yet authoritative 2025-2026 reviews still describe immune maintenance of breast cancer dormancy as postulated rather than established, and dormancy-targeted therapies as clinically unimplemented (Liang et al., Signal Transduction and Targeted Therapy 11, 2026; Ma et al., Frontiers in Immunology 16, 2025; Aguirre-Ghiso et al., Nature Reviews Cancer 26:513-533, 2026).

Problem Statement

Determine whether the predominance of infiltrating T effector (Te, CD44+CD62L-negative) and T effector-memory (Tem, CD44+CD62L-low) cells causally induces and maintains dormancy of disseminated tumor cells during early-stage breast cancer - or is instead a consequence of dormant cells' presence - and establish the mechanistic and kinetic knowledge required to exploit immune-mediated dormancy so as to prevent distant recurrence. Concretely, five linked questions stated or directly implied by the source study must be answered:

  1. Causality: establish interventively, in the FVBN202/neu model of early mammary carcinoma or an equivalent early-dissemination breast cancer model, whether Te/Tem cells actively maintain tumor-cell quiescence in primary site, lung, and liver, whether they merely accompany it, or whether they both maintain and are shaped by it.

  2. Composition-dependent relapse kinetics: in long-term studies following surgical excision of the primary tumor, determine whether dormant-cell populations carrying a higher proportion of Ki67lowKi67^{low} indolent cells relapse faster than populations predominated by Ki67−Ki67^{-} quiescent cells, and quantify the relapse hazard as a function of dormancy composition.

  3. Organ-dependent dormancy logic: identify which factor class - tumor-intrinsic programs, organ-specific microenvironmental factors (lung versus liver, for example stellate-cell versus macrophage or endothelial niches), or therapy-associated immunoediting - explains the observed organ differences in dormancy composition, in PD-L1 upregulation on dormant cells and PD-1 modulation on infiltrating T cells, and in the differential ex vivo recovery and growth of dormant cells.

  4. Impact of therapy-associated immunoediting: establish mechanistically how chemotherapy- and immunotherapy-associated immunoediting (PD-L1 upregulation on dormant cells, PD-1 changes on T cells) affects long-term relapse risk and the efficacy of subsequent immune interventions.

  5. Translational exploitation: determine whether and how immunotherapy can be safely and effectively administered during the clinical dormancy window - including antigen selection (for example semi-allogeneic or mutant neoantigens such as nonself neu), timing relative to surgery and chemotherapy, and the need to overcome therapy-induced checkpoint changes - to either eliminate dormant cells or hold them dormant and thereby prevent distant recurrence.

These components form one program: (1)-(3) establish the causal, organ-resolved mechanism, (4) determines how prior therapy reshapes that mechanism, and (5) is the translational objective the mechanism exists to enable. Establishing the causal role of Te/Tem (or its refutation and replacement by another immune compartment) interventively, characterizing relapse kinetics as a function of dormancy composition and organ, identifying the factor class responsible for the organ-dependent differences in dormancy composition and ex vivo recovery, defining the immunoediting mechanism and its consequences, and validating the resulting principles for dormancy-window immunotherapy preclinically define the research program, with clinical translation as the long-horizon objective.

References

  1. Aqbi HF, Coleman C, Zarei M, Manjili SH, Graham L, Koblinski J, Guo C, Xie Y, Guruli G, Bear HD, Idowu MO, Habibi M, Wang X-Y, Manjili MH. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets. Breast Cancer Research 22:116 (2020). doi:10.1186/s13058-020-01357-9, https://doi.org/10.1186/s13058-020-01357-9 (source paper)
  2. Tallon de Lara P, Castanon H, Vermeer M, Nunez N, Silina K, Sobottka B, Urdinez J, Cecconi V, Yagita H, Movahedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, van den Broek M. CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. Nature Communications 12:769 (2021). doi:10.1038/s41467-021-21045-2, https://doi.org/10.1038/s41467-021-21045-2
  3. Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tuting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Holzel M, Mackay LK, Waithman J, Gebhardt T. Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin. Nature 565:366-371 (2019). doi:10.1038/s41586-018-0812-9, https://doi.org/10.1038/s41586-018-0812-9
  4. Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE, Linde IL, Guerrero M, Veatch JR, Snyder AG, Welm AL, Riddell SR, Ghajar CM. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell 42:119-134.e12 (2024). doi:10.1016/j.ccell.2023.12.011, https://doi.org/10.1016/j.ccell.2023.12.011
  5. Gupta K, Koelsch N, Neely V, Graham L, Bear HD, Idowu MO, Harada H, Manjili MH. Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis. British Journal of Cancer 134:676-684 (2025). doi:10.1038/s41416-025-03292-y, https://doi.org/10.1038/s41416-025-03292-y
  6. Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, Bruno S, Schmidt A, Mertz K, Volkmann K, Terracciano L, Zippelius A, Vetter M, Kurzeder C, Weber WP, Bentires-Alj M. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature 594:566-571 (2021). doi:10.1038/s41586-021-03614-z, https://doi.org/10.1038/s41586-021-03614-z
  7. Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell 185:1694-1708.e19 (2022). doi:10.1016/j.cell.2022.03.033, https://doi.org/10.1016/j.cell.2022.03.033
  8. Liang Y, Chen WM, Zhang Y, Li L. Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis. Signal Transduction and Targeted Therapy 11:1 (2026). doi:10.1038/s41392-025-02328-2, https://doi.org/10.1038/s41392-025-02328-2
  9. Ma H, Zhang B, Chen M, Song Z, Zhao Y. Unraveling the Mystery of Breast Cancer Dormancy: Insights into Genetic, Receptor, and Cellular Interactions Driving Late Recurrence. Frontiers in Immunology 16:1657383 (2025). doi:10.3389/fimmu.2025.1657383, https://doi.org/10.3389/fimmu.2025.1657383
  10. Aguirre-Ghiso JA, Bravo-Cordero JJ, Guo W, Lauvau G, Sosa MS. The sleeping threat: targeting cancer dormancy to transform metastasis therapy. Nature Reviews Cancer 26:513-533 (2026). doi:10.1038/s41568-026-00928-w, https://doi.org/10.1038/s41568-026-00928-w